{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:22:41Z","timestamp":1787394161313,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jphs.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:24:48Z","timestamp":1784042688000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sunitinib causes thrombocytopenia by suppressing megakaryocyte proliferation"],"prefix":"10.1016","volume":"162","author":[{"given":"Moemi","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-145X","authenticated-orcid":false,"given":"Tadahiro","family":"Hashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sou","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamihide","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21873\/cdp.10072","article-title":"Improvement of medical treatment in Japanese patients with metastatic renal cell carcinoma","volume":"2","author":"Fujiwara","year":"2022","journal-title":"Cancer Diagn Progn"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","article-title":"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"36","key":"10.1016\/j.jphs.2026.07.002_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034983","article-title":"Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.jphs.2026.07.002_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00479","article-title":"Comparative efficacy, safety, and costs of sorafenib vs. sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Deng","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jphs.2026.07.002_bib6","article-title":"Meta-analysis of ABCG2 and ABCB1 polymorphisms with sunitinib-induced toxicity and efficacy in renal cell carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-017-3205-9","article-title":"Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma","volume":"17","author":"Kato","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","article-title":"Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: asian versus Non-Asian subgroup analysis of the COMPARZ trial","volume":"11","author":"Guo","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jphs.2026.07.002_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jjco\/hyv126","article-title":"Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor","volume":"45","author":"Komatsu","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jphs.2026.07.002_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015424","article-title":"Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"98","author":"Jin","year":"2019","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.jphs.2026.07.002_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1248\/bpb.b21-01098","article-title":"Dose individualization of oral multi-kinase inhibitors for the implementation of therapeutic drug monitoring","volume":"45","author":"Noda","year":"2022","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1248\/bpb.b14-00636","article-title":"Pharmacokinetic\u2013pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma","volume":"38","author":"Nagata","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3892\/ol.2012.779","article-title":"Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations","volume":"4","author":"Hashita","year":"2012","journal-title":"Oncol Lett"},{"issue":"5845","key":"10.1016\/j.jphs.2026.07.002_bib14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1126\/science.1146304","article-title":"Dynamic visualization of thrombopoiesis within bone marrow","volume":"317","author":"Junt","year":"2007","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jphs.2026.07.002_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.jphs.2026.07.002_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.stem.2014.01.011","article-title":"Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells","volume":"14","author":"Nakamura","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.jphs.2026.07.002_bib17","first-page":"1295","article-title":"Sunitinib induced immune thrombocytopenia","volume":"14","author":"Shekarriz","year":"2015","journal-title":"Iran J Pharm Res"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3747\/co.v15i3.233","article-title":"Drug-induced immune thrombocytopenic purpura secondary to sunitinib","volume":"15","author":"Trinkaus","year":"2008","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1752-1947-7-54","article-title":"Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report","volume":"7","author":"Ansari","year":"2013","journal-title":"J Med Case Rep"},{"issue":"10","key":"10.1016\/j.jphs.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.stemcr.2019.11.011","article-title":"iPSC-Derived platelets depleted of HLA class I are inert to Anti-HLA class I and natural killer cell immunity","volume":"14","author":"Suzuki","year":"2020","journal-title":"Stem Cell Rep"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12987-020-00197-1","article-title":"Inhibition of transforming growth factor beta signaling pathway promotes differentiation of human induced pluripotent stem cell-derived brain microvascular endothelial-like cells","volume":"17","author":"Yamashita","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"5","key":"10.1016\/j.jphs.2026.07.002_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"issue":"7","key":"10.1016\/j.jphs.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"issue":"W1","key":"10.1016\/j.jphs.2026.07.002_bib26","doi-asserted-by":"crossref","first-page":"W338","DOI":"10.1093\/nar\/gkad335","article-title":"Updated MS2PIP web server supports cutting-edge proteomics applications","volume":"51","author":"Declercq","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1038\/s41467-025-64870-5","article-title":"Koina: democratizing machine learning for proteomics research","volume":"16","author":"Lautenbacher","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0301-472X(99)00124-1","article-title":"Polyploidy: occurrence in nature, mechanisms, and significance for the megakaryocyte-platelet system","volume":"28","author":"Zimmet","year":"2000","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.jphs.2026.07.002_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"issue":"5","key":"10.1016\/j.jphs.2026.07.002_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12185-016-1984-4","article-title":"Cell cycle regulation of hematopoietic stem or progenitor cells","volume":"103","author":"Hao","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jphs.2026.07.002_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.916682","article-title":"Cyclin-dependent kinase inhibitors in malignant hematopoiesis","volume":"12","author":"Schirripa","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jphs.2026.07.002_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15283\/ijsc20033","article-title":"Overexpression of p21 has inhibitory effect on human hematopoiesis by blocking generation of CD43+ cells via cell-cycle regulation","volume":"13","author":"Zeng","year":"2020","journal-title":"Int J Stem Cells"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib33","first-page":"787","article-title":"P27 deletion enhances hematopoiesis by paracrine action of IL22 secreted from bone marrow mesenchymal stem cells","volume":"12","author":"Lu","year":"2020","journal-title":"Am J Transl Res"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jphs.2024.01.002","article-title":"Blockade of vasoactive intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 cells","volume":"154","author":"Asano","year":"2024","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.jphs.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jphs.2024.01.007","article-title":"Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0\/G1-S transition by downregulating cyclin D1 via p38 MAPK activation","volume":"154","author":"Zhou","year":"2024","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphs.2024.02.015","article-title":"Gallic acid ameliorates endometrial hyperplasia through the inhibition of the PI3K\/AKT pathway and the down-regulation of cyclin D1 expression","volume":"155","author":"Zheng","year":"2024","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13008-024-00115-z","article-title":"CIP\/KIP and INK4 families as hostages of oncogenic signaling","volume":"19","author":"Csergeov\u00e1","year":"2024","journal-title":"Cell Div"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00018-002-8410-1","article-title":"Regulation of cyclin-Cdk activity in mammalian cells","volume":"59","author":"Obaya","year":"2002","journal-title":"CMLS Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcb.2011.10.004","article-title":"Multiple degradation pathways regulate versatile CIP\/KIP CDK inhibitors","volume":"22","author":"Starostina","year":"2012","journal-title":"Trends Cell Biol"},{"issue":"12","key":"10.1016\/j.jphs.2026.07.002_bib40","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"28","key":"10.1016\/j.jphs.2026.07.002_bib41","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jphs.2026.07.002_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2023.09.010","article-title":"Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer","volume":"178","author":"Zammarrelli","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.jphs.2026.07.002_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70217","article-title":"Transcriptome profiling of megakaryocytes and platelets: application to GP9- and IKZF5-related thrombocytopenia","volume":"9","author":"De Wispelaere","year":"2025","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.jphs.2026.07.002_bib44","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor Receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","article-title":"Normal and oncogenic forms of the receptor tyrosine kinase Kit","volume":"23","author":"Lennartsson","year":"2005","journal-title":"Stem Cell"},{"issue":"1","key":"10.1016\/j.jphs.2026.07.002_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V90.1.148.148_148_155","article-title":"Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli","volume":"90","author":"K\u00f6nig","year":"1997","journal-title":"Blood"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132600040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132600040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:22:50Z","timestamp":1787390570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132600040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S134786132600040X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2026.07.002","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib causes thrombocytopenia by suppressing megakaryocyte proliferation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}